The multicenter TASTE-2 trial reveals that edaravone dexborneol significantly increases the likelihood of functional independence at 90 days for acute ischaemic stroke patients undergoing thrombectomy, particularly those presenting with a clinical-radiological mismatch, while maintaining a safety profile comparable to placebo.